Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
If the late data keeps tracking Phase 2, Health Canada and FDA approval looks plausible around 2027 or 2028
It binds with high affinity across multiple melanocortin receptor subtypes: MC1R (Ki approximately 0.67 nM), MC4R (approximately 6.6 nM), MC3R (approximately 34 nM), and MC5R (approximately 46 nM)
This triple agonist approach distinguishes retatrutide peptide Canada research products from dual agonists such as tirzepatide (GLP-1R/GIPR) and single agonists such as semaglutide (GLP-1R only)
Potential positive long-term impact of GLP-1 medications As for the overall long-term impact, the information currently available is more positive than negative, though more studies need to be conducted
Preferred injection sites include the abdomen (avoiding a two-inch radius around the navel), outer thigh, and back of the upper arm
